J. Terwey

发表

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

M. Peeters, V. Gastañaga, Aliki Taylor, 2015, European journal of cancer.

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.

V. Heinemann, J. Douillard, F. Rivera, 2016, European journal of cancer.

First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.

J. Hecht, G. Fasola, J. Canon, 2015 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

549PIMPACT OF TUMOUR RAS/BRAF STATUS ON EFFICACY OF FIRST-LINE PANITUMUMAB + FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC).

R. Greil, C. Köhne, R. Hofheinz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC).

J. Tabernero, J. Canon, G. Bodoky, 2015 .

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

J. Trojan, P. Fabián, L. Mineur, 2017, BMC Cancer.

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review

J. Trojan, P. Fabián, L. Mineur, 2015, PloS one.

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status

J. Douillard, M. Peeters, F. Rivera, 2015, Drugs.

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

G. Tonini, J. van den Bosch, H. Tessen, 2016, Cancer management and research.

Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer.

J. Tabernero, J. Douillard, M. Peeters, 2015, European journal of cancer.

547PIMPACT OF BASELINE AGE ON EFFICACY AND SAFETY OF FIRST-LINE PANITUMUMAB (PMAB) + FOLFOX4 VS FOLFOX4 TREATMENT.

J. Tabernero, J. Douillard, M. Peeters, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-0004THE PRIME STUDY: SURVIVAL OUTCOMES IN PATIENTS WITH KRAS/NRAS WILD-TYPE METASTATIC COLORECTAL CANCER AND NON-LIVER-LIMITED DISEASE

J. Tabernero, J. Douillard, R. Sidhu, 2014 .

Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.

R. Pirker, J. Vansteenkiste, M. Hedenus, 2016, Clinical therapeutics.

548PIMPACT OF BASELINE COVARIATES AND PRIOR THERAPY ON THE EFFICACY OF SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

M. Peeters, V. Gastañaga, Aliki Taylor, 2015, European journal of cancer.

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.

V. Heinemann, J. Douillard, F. Rivera, 2016, European journal of cancer.

A study-level meta-analysis of efﬁcacy data from head-to-head ﬁrst-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer

J. Douillard, J. Terwey, R. Koukakis, 2022 .

546PTUMOUR SHRINKAGE AND RESPONSE OUTCOMES DURING SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT.

F. Lordick, C. Punt, M. Ducreux, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.